Answers are grounded in this paper and cite their sources.
Aim To determine the levels of Deoxypyridinoline in the Gingival Crevicular Fluid of systemically healthy subjects, stage II and stage III periodontitis patients and to correlate it with clinical periodontal parameters to test its diagnostic accuracy as a biomarker. Materials and methods Eighty voluntary participants, aged 25- 55 years, both male and female, were clinically and radiographically examined. They were then allotted into two groups, Group-A (healthy, n = 40) and Group-B (Stage II - Stage III periodontitis, n = 40). GCF samples were collected and stored in Eppendorf tube containing 0.5 ml phosphate buffer at −80C until further use. The samples were thawed and analyed for Deoxypyridinoline levels using a Human Deoxypyridinoline Sandwich ELISA kit. Results The mean Deoxypyridinoline levels in Group A were 48 ± 12.48 nmol/L and 78 ± 28.45 nmol/L in Group B patients, which was statistically significant ( p < 0.001*). A weak positive correlation was found between all clinical periodontal parameters and Deoxypyridinoline levels in periodontitis patients. Receiver Operator Curves which integrated data from Gingival crevicular fluid samples delivered diagnostic accuracy. Area Under Curve was calculated as 0.88 ± 0.04 ( p ≤ 0.01*) indicating adequate sensitivity and specificity. Conclusion Assessing Deoxypyridinoline levels in GCF provides a secure, non-intrusive, and effective biological sample to detect periodontal tissue inflammation and bone loss. Although DPD demonstrates favourable discriminatory ability, the diagnostic threshold values remain exploratory given the cross-sectional design. Longitudinal validation is required before clinical application, and hence DPD can be considered as an adjunctive rather than definitive diagnostic biomarker for periodontal disease.
No takes yet. Share an insight, caveat, or question.
Nivedha et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: